Premature graying of hair: Risk factors, co-morbid conditions, pharmacotherapy and reversal - A systematic review and meta-analysis
Mahendiratta S
Published in Dermatologic Therapy
Methodology
Systematic review and meta-analysis of PubMed, EMBASE, OVID, Web of Science, Scopus and Google Scholar to 20 January 2019, including studies reporting risk factors, co-morbid conditions, pharmacotherapy and reversal of premature greying of hair.
Key Findings
This systematic review of databases through January 2019 examined risk factors and treatments for premature greying of hair. Factors associated with greying included smoking, deficiencies of vitamin B12, folic acid and biotin, low serum calcium and ferritin, family history, obesity, high blood pressure, lack of exercise, dyslipidaemia, thyroid disorders, hyperuricaemia and altered liver function, and premature greying was flagged as a marker of coronary artery disease, especially in smokers. Among drug treatments only a low-grade recommendation (2A) could be given to calcium pantothenate, PABA and their combination; Anu-tailam was the only herbal agent studied clinically. Treating accompanying conditions led to reversal of greying in many cases.
Conclusions
Smoking and deficiencies of B12, folic acid, biotin, calcium and ferritin are associated with premature graying.
Limitations
The evidence base is thin and largely observational, with the only pharmacological recommendation graded low (2A); reversal reports come from case-level observation rather than controlled trials.
Supplements Studied
Vitamin deficiency (B12, folic acid, and B7) is found to be associated with PGH.
Vitamin deficiency (B12, folic acid, and B7) is found to be associated with PGH.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.